Topotecan Liposomes: A Visit from a Molecular to a Therapeutic Platform

Area of Science:

• Oncology
• Nanotechnology
• Pharmaceutics

Background:

• Topotecan (TPT), a camptothecin analog, exhibits anticancer activity against ovarian, lung, breast cancers, and leukemia.
• Liposomes are explored as nanocarriers for TPT delivery, but face challenges like low encapsulation and drug instability.
• Issues such as pH-labile E ring, accelerated blood clearance, multidrug resistance, and cancer metastasis hinder TPT liposome (TL) efficacy.

Purpose of the Study:

• To review challenges associated with Topotecan liposome (TL) delivery.
• To discuss strategies for overcoming these challenges, including modified liposomes and advanced encapsulation techniques.
• To explore potential applications and the preclinical/clinical outlook for engineered TLs.

Main Methods:

• Review of literature on Topotecan liposome (TL) formulations and delivery challenges.
• Discussion of modifications to TLs, including zwitterionic poly(carboxybetaine) and stimuli-sensitive systems.
• Exploration of advanced encapsulation techniques, such as active loading methods and surface modifications (PEGylation, ligand-anchoring).

Main Results:

• Modified TLs, including PEGylated and ligand-anchored versions, show potential for enhanced drug delivery.
• Advanced encapsulation techniques and prolonged dosing intervals can improve TL efficacy and therapeutic outcomes.
• Engineered TLs offer solutions to overcome issues like low encapsulation efficiency and drug hydrolysis.

Conclusions:

• Overcoming challenges in Topotecan liposome (TL) formulation and delivery is crucial for maximizing its therapeutic potential.
• Engineered liposomal systems and advanced encapsulation strategies represent promising avenues for improved cancer treatment.
• Further preclinical and clinical investigations are warranted to fully realize the potential of advanced TLs in oncology.